Venkys (India) Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 1 Jun 2026 | Food Products | Market Cap: ₹2.2K Cr
Poultry segment is expected to grow 5%-10% in volume for FY '26 with improved realizations. Poultry segment revenue expected to grow by around 5% to 10% in FY '26 with better realization anticipated (Vijay Tijare, Page 7). - Animal Health segment projected to grow at approximately 20% in FY '26, building on consistent past growth (Deepak Khosla, Pages 7, 18). - Oilseed segment profitability expected to improve with stable soya prices; however, not likely to reach past peak EBIT levels (J.K.
From Venkys (India) Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,507
Market Cap
₹2.2K Cr
P/E Ratio
12.4
How does Venkys (India) Ltd rank in Food Products?
Compare Venkys (India) Ltd against every Food Products company this quarter on revenue, margins and earnings-call signals.
Venkys (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.1K Cr, net profit ₹101 Cr.
Full financials →📊 Revenue & Sales Performance
- →Poultry segment is expected to grow 5%-10% in volume for FY '26 with improved realizations.
- →Animal Health (AHP) segment targets around 15%-20% growth; INR 340 crores revenue expected in FY '25 with 15% growth guidance for FY '26.
- →Expansion in SPF eggs capacity by 40,000 bird placements ongoing; potential for increased output if demand materializes.
- →Processed food (ready-to-eat/cook) segment growth projected at 25%-30% next year.
- →Soybean segment expects about 25% growth after degrowth last year.
- →New products and export initiatives underway to drive consistent and futuristic growth.
- →Marketing spends focused on quick commerce and e-commerce channels to fuel processed product sales growth.
- →Margin improvements expected with new capacities and processing plants stabilizing in Animal Health and other divisions.
📈 Profitability & Margins
- →Poultry segment revenue expected to grow by around 5% to 10% in FY '26 with better realization anticipated (Vijay Tijare, Page 7).
- →Animal Health segment projected to grow at approximately 20% in FY '26, building on consistent past growth (Deepak Khosla, Pages 7, 18).
- →Oilseed segment profitability expected to improve with stable soya prices; however, not likely to reach past peak EBIT levels (J.K. Handa, Page 13).
- →SPF egg production expansion (INR 70 crores capex) underway, with capacity utilization currently at 60-65%, expected to enhance future earnings but takes about 2 years to fully contribute (J.K. Handa, Pages 11-12).
- →Ready-to-eat and ready-to-cook segments (retail and QSR) currently ~10% of poultry revenue and expected to grow by 25-30%, with Animal Health also contributing ~10%, providing pricing power and margin stability (Page 17).
- →Overall optimistic outlook with stable commodity prices and capacity expansions supporting moderate growth in operating earnings and profits.
🏗️ Capital Expenditure Plans
- →INR 70 crores capex planned for SPF (Specific Pathogen Free) egg expansion; expected to complete in about 1 year and take 2 years to reach full production. Current SPF capacity utilization is 60-65%; expansion will add capacity of around 40,000 birds annually.
- →New animal health plant commissioned recently, operating at 55-60% capacity; exploring new product lines, expected to improve margins and contribute to 20% revenue growth in AHP segment for FY '26.
- →Strategic initiatives include starting production of ready-to-cook spices in the next quarter, targeting both local and export markets with authentic Indian taste products.
- →Focus on stable commodity prices (especially soya) to control production costs; maize price outlook uncertain and affects broiler hatching egg production costs.
- →Capacity expansions complemented by regulatory clearances and expected sustainable, respectable growth in coming years.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
- →The company has ongoing capital expenditure plans, such as the INR 70 crore expansion for SPF capacity and new plant commissioning for the Animal Health segment.
- →Existing capital expenditure is funded internally, with no direct reference to raising funds via debt or equity.
- →The company appears focused on capacity expansion, product innovation, and improving utilization, financed through operational cash flows.
- →No queries or answers during the call highlight intentions for new fundraising activities.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Venkys (India) Ltd Q4 FY25 results?
Poultry segment is expected to grow 5%-10% in volume for FY '26 with improved realizations. Poultry segment revenue expected to grow by around 5% to 10% in FY '26 with better realization anticipated (Vijay Tijare, Page 7). - Animal Health segment projected to grow at approximately 20% in FY '26, building on consistent past growth (Deepak Khosla, Pages 7, 18). - Oilseed segment profitability expected to improve with stable soya prices; however, not likely to reach past peak EBIT levels (J.K.
What is Venkys (India) Ltd share price analysis?
Venkys (India) Ltd currently shows a neutral. The stock trades at a P/E of 12.4 with a market cap of ₹2,153 Cr. Investors should review the full earnings analysis for detailed insights.
Is Venkys (India) Ltd planning capital expenditure?
INR 70 crores capex planned for SPF (Specific Pathogen Free) egg expansion; expected to complete in about 1 year and take 2 years to reach full production.
Keep Venkys (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.